Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
1
SONN Quote, Financials, Valuation and Earnings
Last price:
$1.26
Seasonality move
:
-4.34%
Day range:
$1.26 - $1.26
52-week range:
$1.08 - $19.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.33x
P/B ratio:
15.39x
Volume:
--
Avg. volume:
1M
1-year change:
-26.32%
Market cap:
$7.9M
Revenue:
$18.6K
EPS (TTM):
-$3.40
Analysts' Opinion
-
Consensus RatingSonnet BioTherapeutics Holdings, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $20.00, Sonnet BioTherapeutics Holdings, Inc. has an estimated upside of 1487.3% from its current price of $1.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $1.26.
Fair Value
-
According to the consensus of 1 analyst, Sonnet BioTherapeutics Holdings, Inc. has 1487.3% upside to fair value with a price target of $20.00 per share.
SONN vs. S&P 500
-
Over the past 5 trading days, Sonnet BioTherapeutics Holdings, Inc. has underperformed the S&P 500 by -66.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sonnet BioTherapeutics Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sonnet BioTherapeutics Holdings, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sonnet BioTherapeutics Holdings, Inc. reported revenues of --.
Earnings Growth
-
Sonnet BioTherapeutics Holdings, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sonnet BioTherapeutics Holdings, Inc. reported earnings per share of -$0.95.
Enterprise value:
7.6M
EV / Invested capital:
--
Price / LTM sales:
3.33x
EV / EBIT:
--
EV / Revenue:
7.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.74x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$911.9K
Return On Assets:
-313.2%
Net Income Margin (TTM):
-1355.62%
Return On Equity:
-1790.87%
Return On Invested Capital:
-1563.18%
Operating Margin:
-284.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $173.3K | $55.9K | $1M | -- | -- | |
| Gross Profit | $99.1K | -$25.1K | $911.9K | -$21K | -$22.2K | |
| Operating Income | -$22.2M | -$12.3M | -$14M | -$3.5M | -$3.8M | |
| EBITDA | -$22.1M | -$12.2M | -$14M | -$3.5M | -$3.8M | |
| Diluted EPS | -$517.15 | -$24.20 | -$8.22 | -$5.57 | -$0.95 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7M | $7.2M | $9.6M | $5.1M | $1.3M | |
| Total Assets | $7.2M | $7.5M | $10M | $5.8M | $2.1M | |
| Current Liabilities | $5.8M | $6.5M | $6.5M | $3.1M | $5.1M | |
| Total Liabilities | $5.8M | $6.7M | $6.6M | $3.2M | $5.1M | |
| Total Equity | $1.4M | $764.2K | $3.4M | $2.6M | -$3M | |
| Total Debt | $147.5K | $221.3K | $150.2K | $68.8K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.9M | -$10M | -$10.3M | -$3.1M | -$1.8M | |
| Cash From Investing | -$297.8K | -$182K | -$12K | -$12K | -- | |
| Cash From Financing | $25M | $6.7M | $7.1M | $2.8M | $21K | |
| Free Cash Flow | -$23.2M | -$10.2M | -$10.3M | -$3.1M | -$1.8M | |
SONN
Sector
Market Cap
$7.9M
$28.5M
Price % of 52-Week High
6.53%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-197.75%
-1.33%
1-Year Price Total Return
-26.32%
-20.32%
Beta (5-Year)
1.478
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.52
200-day SMA
Sell
Level
$3.01
Bollinger Bands (100)
Sell
Level
3 - 5.5
Chaikin Money Flow
Sell
Level
-26.9M
20-day SMA
Sell
Level
$3.94
Relative Strength Index (RSI14)
Sell
Level
28.16
ADX Line
Sell
Level
19.33
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$4.34
MACD (12, 26)
Sell
Level
-0.82
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
111.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-73.2185)
Sell
CA Score
(Annual)
Level (-16.173)
Buy
Beneish M-Score
(Annual)
Level (-3.4235)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (17.0417)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, SONN has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SONN average analyst price target in the past 3 months is $20.00.
-
Where Will Sonnet BioTherapeutics Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sonnet BioTherapeutics Holdings, Inc. share price will rise to $20.00 per share over the next 12 months.
-
What Do Analysts Say About Sonnet BioTherapeutics Holdings, Inc.?
Analysts are divided on their view about Sonnet BioTherapeutics Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sonnet BioTherapeutics Holdings, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Sonnet BioTherapeutics Holdings, Inc.'s Price Target?
The price target for Sonnet BioTherapeutics Holdings, Inc. over the next 1-year time period is forecast to be $20.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SONN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sonnet BioTherapeutics Holdings, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SONN?
You can purchase shares of Sonnet BioTherapeutics Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sonnet BioTherapeutics Holdings, Inc. shares.
-
What Is The Sonnet BioTherapeutics Holdings, Inc. Share Price Today?
Sonnet BioTherapeutics Holdings, Inc. was last trading at $1.26 per share. This represents the most recent stock quote for Sonnet BioTherapeutics Holdings, Inc.. Yesterday, Sonnet BioTherapeutics Holdings, Inc. closed at $1.26 per share.
-
How To Buy Sonnet BioTherapeutics Holdings, Inc. Stock Online?
In order to purchase Sonnet BioTherapeutics Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SONN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SONN
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
15.39x
1.83x
Price / LTM sales
3.33x
1.60x
Growth Metrics
SONN
Sector
Revenue growth
5268.84%
4.85%
Earnings growth
83.04%
11.11%
Revenue (5-year growth)
-77.19%
6.45%
Earnings forecast
-$0.49
-$0.20
Profitability
SONN
Sector
Profitability FY 2024
-$64.5K
$3.6M
Return on invested capital
-1563.18%
-30.98%
Return on assets
-313.2%
-27.62%
Return on equity
-1790.87%
-36.69%
Earnings Date
Last Earnings Date
Dec
8
Next Earnings Date
Dec
8
Estimated Next Earnings Date
Mar
9
Balance Sheet
SONN
Sector
Total cash
$321.3K
$27.2M
Short term investments
--
$25.7M
Total assets
$2.8M
$79.7M
Long term debt
$68.8K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 67.26% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.66% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.37% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
